Conference Proceedings

A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)

KN Chi, D Rathkopf, G Attard, MR Smith, E Efstathiou, D Olmos, EJ Small, JY Lee, P Sieber, C Dunshee, D Ricci, JS Simon, X Zhao, N Kothari, S Cheng, SK Sandhu

ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2019

Grants

Funding Acknowledgements

Janssen Pharmaceuticals.